4.7 Article

Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 24, Pages 16860-16878

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c01659

Keywords

-

Funding

  1. Dusseldorf School of Oncology-Netzwerkverbundes and Forschungskommission [2018-04]
  2. KinderKrebsForschung e.V.
  3. Deutsche Forschungsgemeinschaft ( DFG, German Research Foundation) [270650915, GRK 2158]
  4. TransOnc priority program of the German Cancer [70112951]
  5. Katharina-Hardt Foundation
  6. Christiane und Claudia Hempelfoundation
  7. especially Lowenstern e.V.

Ask authors/readers for more resources

In this study, we achieved the chemical knockdown of histone deacetylase 6 (HDAC6) using proteolysis targeting chimera (PROTAC) technology. Two series of cereblon-recruiting PROTACs were synthesized, allowing the rapid preparation of HDAC6 degrader mini libraries. Both PROTAC series demonstrated selective degradation of HDAC6 in leukemia cell lines.
In this work, we utilized the proteolysis targeting chimera (PROTAC) technology to achieve the chemical knockdown of histone deacetylase 6 (HDAC6). Two series of cereblonrecruiting PROTACs were synthesized via a solid-phase parallel synthesis approach, which allowed the rapid preparation of two HDAC6 degrader mini libraries. The PROTACs were either based on an unselective vorinostat-like HDAC ligand or derived from a selective HDAC6 inhibitor. Notably, both PROTAC series demonstrated selective degradation of HDAC6 in leukemia cell lines. The best degraders from each series (denoted A6 and B4) were capable of degrading HDAC6 via ternary complex formation and the ubiquitin-proteasome pathway, with DC50 values of 3.5 and 19.4 nM, respectively. PROTAC A6 demonstrated promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines. These findings highlight the potential of this series of degraders as effective pharmacological tools for the targeted degradation of HDAC6.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma

Anne Schedel, Ulrike Anne Friedrich, Mina N. F. Morcos, Rabea Wagener, Juha Mehtonen, Titus Watrin, Claudia Saitta, Triantafyllia Brozou, Pia Michler, Carolin Walter, Asta Foersti, Arka Baksi, Maria Menzel, Peter Horak, Nagarajan Paramasivam, Grazia Fazio, Robert J. Autry, Stefan Froehling, Meinolf Suttorp, Christoph Gertzen, Holger Gohlke, Sanil Bhatia, Karin Wadt, Kjeld Schmiegelow, Martin Dugas, Daniela Richter, Hanno Glimm, Merja Heinaniemi, Rolf Jessberger, Gianni Cazzaniga, Arndt Borkhardt, Julia Hauer, Franziska Auer

Summary: Mutations in RAD21 gene in germline are associated with childhood lymphoblastic leukemia or lymphoma without CdLS phenotype.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biochemistry & Molecular Biology

Prenylated cyclohexene-type meroterpenoids and sulfur-containing xanthones produced by Pseudopestalotiopsis theae

Sergi Herve Akone, Hao Wang, Eitel Ngoh Misse Mouelle, Attila Mandi, Tibor Kurtan, Pierre Roger Koliye, Rudolf Hartmann, Sanil Bhatia, Jing Yang, Werner E. G. Muller, Daowan Lai, Zhen Liu, Rainer Kalscheuer, Peter Proksch

Summary: Chemical investigation of a fungal endophyte Pseudopestalotiopsis theae isolated from leaves of Caloncoba welwitschii collected in Cameroon has led to the discovery of two previously undescribed sulfur-containing xanthone derivatives sydoxanthones D and E, as well as three previously undescribed monomeric diisoprenyl-cyclohexene-type meroterpenoids biscognienynes D-F and five known natural products.

PHYTOCHEMISTRY (2022)

Article Chemistry, Medicinal

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs

Lukas von Bredow, Thomas Martin Schafer, Julian Hogenkamp, Maik Tretbar, Daniel Stopper, Fabian B. Kraft, Julian Schliehe-Diecks, Andrea Scholer, Arndt Borkhardt, Sanil Bhatia, Jana Held, Finn K. Hansen

Summary: This study presents the design, synthesis, and biological evaluation of a mini library of dihydroartemisinin-HDACi hybrid molecules. The hybrid molecules showed potent activity against P. falciparum parasites and leukemia cell lines, indicating their potential as antimalarial and antileukemia drug leads.

PHARMACEUTICALS (2022)

Article Medicine, General & Internal

PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120

Grazia Fazio, Silvia Bresolin, Daniela Silvestri, Manuel Quadri, Claudia Saitta, Elena Vendramini, Barbara Buldini, Chiara Palmi, Michela Bardini, Andrea Grioni, Silvia Rigamonti, Marta Galbiati, Stefano Mecca, Angela Maria Savino, Alberto Peloso, Jia-Wey Tu, Sanil Bhatia, Arndt Borkhardt, Concetta Micalizzi, Luca Lo Nigro, Franco Locatelli, Valentino Conter, Carmelo Rizzari, Maria Grazia Valsecchi, Geertruij te Kronnie, Andrea Biondi, Giovanni Cazzaniga

Summary: This study provides new insights into high-risk Ph-like leukemia and identifies a potential therapy for targeting the PAX5-fusion poor-risk group.

EBIOMEDICINE (2022)

Article Chemistry, Medicinal

Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia

Nina Ressing, Julian Schliehe-Diecks, Paris R. Watson, Melf Soennichsen, Abigail D. Cragin, Andrea Schoeler, Jing Yang, Linda Schaeker-Huebner, Arndt Borkhardt, David W. Christianson, Sanil Bhatia, Finn K. Hansen

Summary: By using a microwave-assisted protocol, 16 peptoid-capped HDAC inhibitors were synthesized with fluorinated linkers, resulting in the identification of two active compounds. Compound 10h displayed potent and unselective HDAC inhibition in biochemical and cellular assays, showing remarkable cytotoxic potential against various therapy-resistant leukemia cell lines. Moreover, compound 10h showed synergistic interactions with the DNA methyltransferase inhibitor decitabine in AML cell lines.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors

Luisa M. Bachmann, Maria Hanl, Felix Feller, Laura Sinatra, Andrea Schoeler, Jens Pietzsch, Markus Laube, Finn K. Hansen

Summary: Multi-target drugs (MTDs) offer a new approach for combination therapies. In this study, a library of dual HDAC-COX inhibitors was designed, synthesized, and evaluated. The synthesized compounds showed significant inhibitory activities against HDAC and COX isoforms. Selected compounds were confirmed to have membrane permeability and inhibition of cellular HDAC activity. The most promising dual inhibitors, C3 and C4, demonstrated antiproliferative effects and increased apoptotic cells. However, simultaneous inhibition of HDAC and COX by these inhibitors or combination treatments did not result in additive or synergistic anticancer activities.

MOLECULES (2023)

Article Cell Biology

The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism

Fabian Stuhldreier, Laura Schmitt, Thomas Lenz, Ilka Hinxlage, Marcel Zimmermann, Philipp Wollnitzke, Julian Schliehe-Diecks, Yang Liu, Paul Jaeger, Stefanie Geyh, Nicole Teusch, Christoph Peter, Sanil Bhatia, Rainer Haas, Bodo Levkau, Andreas S. Reichert, Kai Stuehler, Peter Proksch, Bjoern Stork, Sebastian Wesselborg

Summary: Viriditoxin (VDT), derived from Cladosporium cladosporioides, shows promising potential as a candidate for leukemia and lymphoma treatment. It exhibits high cytotoxicity in leukemia and lymphoma cells, while having minimal impact on solid tumor cells. Furthermore, VDT does not affect hematopoietic stem and progenitor cells, making it a potentially effective and safe therapeutic approach.

CELL DEATH & DISEASE (2022)

Article Chemistry, Multidisciplinary

Chemical Synthesis of Alpha-Synuclein Proteins via Solid-Phase Peptide Synthesis and Native Chemical Ligation

Luisa Maria Gatzemeier, Franc Meyer, Ulf Diederichsen, Tiago Fleming Outeiro

Summary: Alpha-Synuclein is a protein involved in neurodegenerative disorders that accumulate in brain protein inclusions. We have developed a chemical synthesis method for Alpha-Synuclein, allowing the synthesis of protein variants for further investigation of its structure and aggregation behavior.

CHEMISTRY-A EUROPEAN JOURNAL (2023)

Article Hematology

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia

Chiara Palmi, Silvia Bresolin, Stefanie Junk, Grazia Fazio, Daniela Silvestri, Marketa Zaliova, Athanasios Oikonomou, Katerina Scharov, Martin Stanulla, Anja Moericke, Martin Zimmermann, Martin Schrappe, Barbara Buldini, Sanil Bhatia, Arndt Borkhardt, Claudia Saitta, Marta Galbiati, Michela Bardini, Luca Lo Nigro, Valentino Conter, Maria Grazia Valsecchi, Andrea Biondi, Geertruy Te Kronnie, Gunnar Cario, Giovanni Cazzaniga

Summary: Children with Down syndrome have an increased risk for B-cell acute lymphoblastic leukemia (DS-ALL) with poor prognosis. This study evaluated the incidence and prognostic value of the Philadelphia-like (Ph-like) profile and IKZF1plus pattern in DS-ALL. The presence of Ph-like signature and IKZF1 deletion were associated with worse outcomes, and ex vivo drug screening showed sensitivity of IKZF1plus blasts to drugs active against Ph-like ALL. Tailored therapeutic strategies are needed for DS-ALL patients with these high-risk features.

HEMASPHERE (2023)

Article Pharmacology & Pharmacy

High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia

Athanasios Oikonomou, Luigia Valsecchi, Manuel Quadri, Titus Watrin, Katerina Scharov, Simona Procopio, Jia-Wey Tu, Melina Vogt, Angela Maria Savino, Daniela Silvestri, Maria Grazia Valsecchi, Andrea Biondi, Arndt Borkhardt, Sanil Bhatia, Giovanni Cazzaniga, Grazia Fazio, Michela Bardini, Chiara Palmi

Summary: This study utilized high-throughput drug screening to identify 9 compounds that are active against BCP-ALL but spare normal cells. It also confirmed the anti-leukemic effect of the BCL2 inhibitor venetoclax. This research provides potential therapeutic options for difficult-to-treat childhood BCP-ALL subgroups.

BIOCHEMICAL PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors

Pawel Stachura, Wei Liu, Haifeng C. Xu, Agnes Wlodarczyk, Olivia Stencel, Piyush Pandey, Melina Vogt, Sanil Bhatia, Daniel Picard, Marc Remke, Karl S. Lang, Dieter Haeussinger, Bernhard Homey, Philipp A. Lang, Arndt Borkhardt, Aleksandra A. Pandyra

Summary: This study identifies a drug called 5-NL that can enhance the ability of T cells to target tumor cells, and it shows improved efficacy when used in combination with PD-1 antibody treatment.

MOLECULAR CANCER (2023)

Article Chemistry, Multidisciplinary

Development of the first geldanamycin-based HSP90 degraders

Silas Wurnig, Melina Vogt, Julian Hogenkamp, Niklas Dienstbier, Arndt Borkhardt, Sanil Bhatia, Finn K. Hansen

Summary: Despite limitations with HSP90 inhibitors as anticancer drugs, a new approach using PROTACs to degrade the protein shows promise. This study focuses on designing and evaluating geldanamycin-based HSP90 degraders based on the PROTAC technology. The best degrader, 3a, effectively reduced HSP90 alpha and HSP90 beta levels in cells using the ubiquitin-proteasome pathway.

FRONTIERS IN CHEMISTRY (2023)

Article Cell Biology

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+leukemia cells

Melina Vogt, Niklas Dienstbier, Julian Schliehe-Diecks, Katerina Scharov, Jia-Wey Tu, Philip Gebing, Julian Hogenkamp, Berna-Selin Bilen, Silke Furlan, Daniel Picard, Marc Remke, Layal Yasin, David Bickel, Munishikha Kalia, Alfredo Iacoangeli, Thomas Lenz, Kai Stuehler, Aleksandra A. Pandyra, Julia Hauer, Ute Fischer, Rabea Wagener, Arndt Borkhardt, Sanil Bhatia

Summary: HSP90 has emerged as an appealing anti-cancer target, but its inhibitors are limited by the development of resistance. This study identified that the loss of HSP90 beta isoform leads to overexpression of HSP90 alpha and extracellular-secreted HSP90 alpha. Additionally, the absence of HSP90 alpha restricts the growth of leukemia cells.

CELL DEATH & DISEASE (2023)

No Data Available